Literature DB >> 1900735

Microbiology of airway disease in patients with cystic fibrosis.

P H Gilligan1.   

Abstract

Individuals with cystic fibrosis have abbreviated life spans primarily due to chronic airway infection. A limited number of types of organisms are responsible for these infections, with Staphylococcus aureus and Pseudomonas aeruginosa being of primary importance. In the pre-antibiotic era, greater than 90% of deaths due to infection were caused by S. aureus and death usually occurred in the first 2 years of life. With the advent of effective antistaphylococcal therapy, life spans increased and P. aeruginosa became the pathogen of primary importance. P. aeruginosa isolates recovered from patients with cystic fibrosis have a unique phenotypic characteristic referred to as "mucoid." The mucoid phenotype is due to the production of a mucoid exopolysaccharide. A mucoid exopolysaccharide is believed to play a central role in the establishment of chronic pseudomonal lung infection in these patients. A third organism, Pseudomonas cepacia, has recently been detected in the airways of older patients with cystic fibrosis and is associated with increased mortality. The virulence of P. cepacia is not understood, but the organism is extremely refractory to antimicrobial therapy. Other bacteria, including Haemophilus influenzae and members of the family Enterobacteriaceae, appear to play a secondary role in airway infection. Aspergillus fumigatus is the most important fungal agent causing allergic bronchopulmonary disease. The role of viruses has only recently been examined. At least in some patients with cystic fibrosis, respiratory syncytial virus may be important in predisposing to subsequent bacterial infections.

Entities:  

Mesh:

Year:  1991        PMID: 1900735      PMCID: PMC358177          DOI: 10.1128/CMR.4.1.35

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  189 in total

1.  A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis.

Authors:  V A Loening-Baucke; E Mischler; M G Myers
Journal:  J Pediatr       Date:  1979-10       Impact factor: 4.406

2.  Bacterial flora of respiratory tract in patients with cystic fibrosis, 1950-71.

Authors:  M B Mearns; G H Hunt; R Rushworth
Journal:  Arch Dis Child       Date:  1972-12       Impact factor: 3.791

3.  Serum precipitins to Aspergillus fumigatus in cystic fibrosis.

Authors:  R H Schwartz; D E Johnstone; D S Holsclaw; R R Dooley
Journal:  Am J Dis Child       Date:  1970-11

4.  Pseudomonas colonization in cystic fibrosis. A study of 160 patients.

Authors:  L L Kulczycki; T M Murphy; J A Bellanti
Journal:  JAMA       Date:  1978-07-07       Impact factor: 56.272

5.  A new polyvalent Pseudomonas vaccine.

Authors:  J M Miler; J F Spilsbury; R J Jones; E A Roe; E J Lowbury
Journal:  J Med Microbiol       Date:  1977-02       Impact factor: 2.472

6.  Pseudomonas aeruginosa infection in cystic fibrosis. Bactericidal effect of serum from normal individuals and patients with cystic fibrosis on P. aeruginosa strains from patients with cystic fibrosis or other diseases.

Authors:  N Holby; S Olling
Journal:  Acta Pathol Microbiol Scand C       Date:  1977-04

7.  Serological typing of Pseudomonas aeruginosa: use of commercial antisera and live antigens.

Authors:  C D Brokopp; R Gomez-Lus; J J Farmer
Journal:  J Clin Microbiol       Date:  1977-06       Impact factor: 5.948

8.  Effect of N-acetylcysteine on antibiotic activity and bacterial growth in vitro.

Authors:  M F Parry; H C Neu
Journal:  J Clin Microbiol       Date:  1977-01       Impact factor: 5.948

9.  Production and characterization of the slime polysaccharide of Pseudomonas aeruginosa.

Authors:  L R Evans; A Linker
Journal:  J Bacteriol       Date:  1973-11       Impact factor: 3.490

10.  Antimicrobial susceptibilities of rough, smooth, and mucoid colony types of Pseudomonas isolated from cystic fibrosis patients.

Authors:  B A Maybury; J Blessing-Moore; S A deWit; N J Lewiston; A S Yeager
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

View more
  191 in total

1.  Stenotrophomonas maltophilia D457R contains a cluster of genes from gram-positive bacteria involved in antibiotic and heavy metal resistance.

Authors:  A Alonso; P Sanchez; J L Martínez
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

Review 2.  Infection control in cystic fibrosis: methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and the Burkholderia cepacia complex.

Authors:  J R Govan
Journal:  J R Soc Med       Date:  2000       Impact factor: 5.344

Review 3.  Taxonomy and identification of the Burkholderia cepacia complex.

Authors:  T Coenye; P Vandamme; J R Govan; J J LiPuma
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

4.  Interaction of pseudomonas aeruginosa with epithelial cells: identification of differentially regulated genes by expression microarray analysis of human cDNAs.

Authors:  J K Ichikawa; A Norris; M G Bangera; G K Geiss; A B van 't Wout; R E Bumgarner; S Lory
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

5.  Identification of bacteria recovered from clinical specimens by 16S rRNA gene sequencing.

Authors:  P Kiratisin; L Li; P R Murray; S H Fischer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10-01       Impact factor: 3.267

6.  Histidine-rich amphipathic peptide antibiotics promote efficient delivery of DNA into mammalian cells.

Authors:  Antoine Kichler; Christian Leborgne; Josefine März; Olivier Danos; Burkhard Bechinger
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-31       Impact factor: 11.205

7.  Use of 16S rRNA gene sequencing for identification of nonfermenting gram-negative bacilli recovered from patients attending a single cystic fibrosis center.

Authors:  Agnes Ferroni; Isabelle Sermet-Gaudelus; Eric Abachin; Gilles Quesne; Gerard Lenoir; Patrick Berche; Jean-Louis Gaillard
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

Review 8.  Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis.

Authors:  Melissa B Miller; Peter H Gilligan
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

Review 9.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

10.  Analysis of promoters controlled by the putative sigma factor AlgU regulating conversion to mucoidy in Pseudomonas aeruginosa: relationship to sigma E and stress response.

Authors:  D W Martin; M J Schurr; H Yu; V Deretic
Journal:  J Bacteriol       Date:  1994-11       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.